bioRxivImmunologyPreprint
Determinants in gammaretroviral Env dictate the production of neutralizing antibodies
Robert Z. ZhangiD, Lia Robben, Ashley Willey, Vincent Mele, Emilia Crow, Sandra Umana, Brady Callahan, Laura Arroyo, Grace W. Graudin, Holly C. SimmonsiD, Kevin R. McCarthyiD, Melissa KaneiD
Abstract
Protective immune responses are shaped by the nature of the infectious pathogen. Some viral infections are self-limiting and stimulate lasting immunity, while others activate poor responses that fail to control the infection or prevent development of disease. Little is known concerning the specific viral determinants that control whether a given viral infection will result in protective immunity. Here, we demonstrate that strains of the gammaretrovirus, murine leukemia virus, differ in their ability to stimulate neutralizing antibody production via a noncanonical pathway. Additionally, we show that virus-specific production of neutralizing immune responses is unique to infection, suggesting that the activation of alternative antibody responses is triggered by the infectious process rather than the unique nature of specific viral antigens. Viral chimeras indicate that activation of neutralizing antiviral antibody production is determined by the receptor-binding domain, and that the surface subunit controls binding to and infection of various cell types. The ability of specific viral factors to determine the outcome of infection and the induction of distinctive immune responses between closely related retroviral strains provides an ideal model for the dissection of both host and viral determinants underlying the control of viral infection and the production of neutralizing antibodies. SUMMARYWe report here that retroviral envelope glycoprotein determines stimulation of GC B cell responses and the production of neutralizing antibodies in the absence of IFN{gamma}-signaling, thus defining the factors that stimulate non-canonical immune responses and further developing the knowledge required for vaccine development.
- organism: mouse
- assay: proteomics
- research focus: host-pathogen & immune response
- research focus: variant calling
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- TLR7-independent control of retroviral infection
Robert Z. Zhang, Lia Robben, … Melissa Kane·bioRxiv·Apr 29, 2026
- B cell response to HCMV gH/UL116 elicits neutralizing and FcγR-activating antibodies
Artem Ashurov, Katja Hoffmann, … Matthias Zehner·bioRxiv·Oct 19, 2026
- Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection
M. L. Goodwin, H. S. Webster, … S. R. Permar·bioRxiv·Jan 14, 2020
- Differential and sequential immunomodulatory role of neutrophils and Ly6Chi inflammatory monocytes during antiviral antibody therapy
J. Lambour, M. Naranjo-Gomez, … M. Pelegrin·bioRxiv·Apr 22, 2020
- Genetic differences between 129S substrains affect antiretroviral immune responses
R. Z. Zhang, V. Mele, … M. Kane·bioRxiv·Aug 10, 2022
- Improving antibody-mediated protection against HSV infection by eliminating interactions with the viral Fc receptor gE/gI
Matthew D. Slein, Iara M. Backes, … Margaret E. Ackerman·Science Translational MedicinePeer-reviewed·Nov 19, 2025